

Catherine H Bozio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/749559/publications.pdf>

Version: 2024-02-01

10
papers

1,516
citations

1162889

8
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

1717
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19â€“Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance â€” VISION Network, 10 States, August 2021â€“January 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 139-145.	9.0	349
2	Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19â€“Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance â€” VISION Network, 10 States, August 2021â€“January 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 255-263.	9.0	350
3	Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19â€“associated hospitalizations among immunocompromised adultsâ€”Nine States, Januaryâ€“September 2021. <i>American Journal of Transplantation</i> , 2022, 22, 306-314.	2.6	11
4	Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19â€“Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5â€“17 Years â€” VISION Network, 10 States, April 2021â€“January 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 352-358.	9.0	148
5	Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19â€“Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults â€” VISION Network, 10 States, December 2021â€“March 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 495-502.	9.0	35
6	Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. <i>New England Journal of Medicine</i> , 2021, 385, 1355-1371.	13.9	353
7	Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19â€“Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity â€” Nine States, Januaryâ€“September 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1539-1544.	9.0	88
8	Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19â€“Associated Hospitalizations Among Immunocompromised Adults â€” Nine States, Januaryâ€“September 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 1553-1559.	9.0	146
9	Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. <i>PLoS ONE</i> , 2020, 15, e0241989.	1.1	8
10	Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine. <i>PLoS ONE</i> , 2018, 13, e0203205.	1.1	28